1 / 47

Pregnancy Loss

Pregnancy Loss. Gregory Zapantis, M.D. Assistant Professor Department of Obstetrics, Gynecology & Women’s Health, Division of Reproductive Endocrinology & Infertility Albert Einstein College of Medicine. Pregnancy Loss.

taline
Download Presentation

Pregnancy Loss

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pregnancy Loss Gregory Zapantis, M.D. Assistant Professor Department of Obstetrics, Gynecology & Women’s Health, Division of Reproductive Endocrinology & Infertility Albert Einstein College of Medicine

  2. Pregnancy Loss • Abortion: Termination of pregnancy before the fetus is sufficiently developed to survive • Pregnancy loss before 20 weeks GA; fetus weighing less than 500 g

  3. Pregnancy Loss: Types • Threatened Abortion: Vaginal bleeding when a viable embryo or fetus is suspected (first 20 wks GA) • Embryonic Demise/ Missed Abortion: Intrauterine embryo with no heart beat (CRL > 4mm) • Blighted Ovum (Anembryonic Pregnancy): Gestational sac without embryonic development at a gestational age or sac size in which such development expected (> 5-6 wks, sac diameter 10-18mm)

  4. Pregnancy Loss: Types • Incomplete Abortion: Any of the above with an incomplete expulsion of the products of conception • Complete Abortion: Any of the above with resultant complete expulsion of the products of conception

  5. Pregnancy Loss • More than 80% of SABs occur before 12 weeks GA, then decrease rapidly (Harlap and Shiono, 1980) • Based on sensitive uCG assay: SAB rate 31% (22% before expected menses; 9% after) (Wilcox et al., 1988) • Maternal age and previous pregnancy history (and paternal age) influence the risk of spontaneous abortion (Wilson et al., 1986)

  6. Previous Pregnancy & SAB Risk (Regan et al., 1989) n=407SAB risk (%) All patients 12 Last preg ab 19 Only ab 24 Last preg nl 5 All preg nl 4 Primigravida 5 Multigravida 14

  7. Age and Risk of SAB (Knudsen et al., 1991) n=19,737SAB risk (%) 11.3 (10.9-11.8) Age 20-29 9.7 (9.2-12.7) 30-34 11.5 (10.6-12.6) 35-39 21.4 (19.2-23.7) 40+ 42.2 (35.1-47.4)

  8. Number of Previous SABs and Risk of SAB (Knudsen et al., 1991) Previous SABsSAB risk (%) 0 10.7 (10.3-11.2) 1 15.9 (15.4-16.4) 2 25.1 (23.4-27) 3 45.0 (39.8-50.4) 4 54.3 (43.7-64.4) Because of this, ACOG advises W/U After 2

  9. Risk of SAB with Fetal Heart Motion (Stenchever et al., 2001) • Fetal heart motion, 5-6 weeks: 6-8%. At 8 weeks: 2% • Fetal heart motion with vaginal bleeding: 15% • Fetal heart motion with a history of recurrent spontaneous abortions: 20-30%

  10. Chromosomal Abnormalities & SABs: Aneuploidy • Occur in 50-85% of SABs • How many more due to undetectable causes? (Lanesa and Hogge, 2000) • 50-67% are trisomies • Trisomies 16 and 22 (also 13,18,21) most common • Due to isolated nondisjunction, maternal or paternal balanced translocation, or balanced chromosomal inversion • 7-15% are 45,X Not associated with advances in parental age • 15% are triploidy; 10% are tetraploidy; 5% are structural

  11. Nondisjunction Most common chromosomal mechanism of aneuploidy Most commonly maternal in origin & most commonly occurs during Meiosis I If paternally derived, nondisjunction in M1=M2 (e.g. Trisomy 21)

  12. Chromosomal Abnormalities & SABs: Euploidy • Later SABs than for aneuploid: ¾ of losses by 13 weeks vs. 8 weeks for aneuploid (Kajii et al., 1980) • Increase dramatically after maternal age of 35 years (Stein et al., 1980) • Reasons unknown; possibly genetic abnormality (e.g. isolated mutation), or maternal or paternal factors

  13. Chromosomal Abnormalities & SABs • Better pregnancy term rate after aneuploid loss (68%) (19 pts) than after euploid loss (41%) (39 pts) (Jivraj et al., 2001) • Benefit to karyotype abortus? ACOG does not recommend routine testing

  14. Infections & SABs • SABs have been independently associated with maternal HIV-1 antibody, maternal syphilis seroreactivity, group B Strep vaginal colonization, HSV genital infection in the first half of pregnancy (Temmerman, 1992) • ? Toxoplasma, Mycoplasma, Ureaplasma

  15. Chronic Diseases & SABs • Chronic wasting diseases (e.g. tuberculosis or carcinomatosis) seldom cause SAB • Celiac sprue has been reported to cause SAB (Sher, 1994)

  16. Drug Use & Environmental Factors & SAB risk • Smoking ≥14 cigarettes a day increases SAB risk by 1.7X (Stenchever et al., 2001) • Alcohol use: 2X SAB risk if used twice weekly; 3X SAB risk if used daily (Stenchever et al., 2001) • Caffeine use: >4 cups, slight  risk (Armstrong et al., 1992)

  17. Drug Use & Environmental Factors & SAB risk • Radiation: No increased risk for congenital malformations and SABs from ionizing radiation at doses < 5 rads (Brent, 1989) • No proven risk 0-8 wks or > 25 wks; harmful range greatest 8-15 wks (Committee on Biological Effects, 1990)

  18. Drug Use & Environmental Factors & SAB risk • Anesthetic gases implicated in SABs: controversial (Axelsson et al., 1982) • Arsenic, lead, formaldehyde, benzene and ethylene oxide may cause abortions (Barlow and Sullivan, 1982)

  19. Aging Gametes & SAB risk • Increased SAB risk if IUI occurred 4 days before or 3 days after ovulation by BBT temperature shift (Guerrero and Rojas, 1975)

  20. Recurrent Spontaneous Abortion (RSA) • Three or more SABs occurs in 0.5-1.0% of couples (Alberman, 1988) • In most women, no cause can be identified (Harger et al., 1983)

  21. Chromosomal Abnormalities & RSA • Occur less likely in SABs from women < age 36 with RSA history (Stephenson et al., 2002) • Higher genetic abnormalities in preimplantation genetic studies than in control IVF patients (Simon et al., 1998) • Significantly higher preterm delivery (13%), SGA (13%), perinatal loss (2.5%), and CS birth (36%) than controls (U.K. study of 162 pregnancies) (Wolf, 1996)

  22. Chromosomal Abnormalities & RSA (Stenchever et al., 2001) • In couples with RSA, prevalence of a structural chromosomal abnormality in either parent: 3-5% • Abnormalities 2X more frequent in female partner • 50% are balanced translocations • 25% are Robertsonian translocations • With translocation, subsequent SAB rate: 80%

  23. Chromosomal Abnormalities & RSA • More common in couples with previous malformed or mentally retarded children • However, ACOG states presence of phenotypically normal offspring does not exclude parental chromosomal abnormalities

  24. Balanced Translocations Balanced Translocations: No loss/gain of chromosomal material. No gene disruption

  25. Robertsonian Translocations

  26. Chromosomal Abnormalities & RSA • Genetic counseling • Donor eggs (Remohi et al., 1996) ; donor sperm (Rubio, 1999) ; donor embryos • ACOG recommends preimplantation genetic diagnosis (PGD) if parental structural defect is determined

  27. Uterine Factor & RSA: Evaluation • Hysterosalpingogram • Very sensitive for Mullerian abnormalities • Hysterosonogram • More sensitive for myomas and polyps (Goldberg et al., 1997; Keltz et al., 1997) • MRI • Hysteroscopy/ Laparoscopy • Gold standard

  28. Uterine Factor & RSA: Evaluation Hysterosalpingogram (HSG)

  29. Uterine Factor & RSA: Evaluation Hysterosalpingogram (HSG) Intrauterine Adhesions Septated Uterus Polyps Bicornuate Uterus

  30. Uterine Factor & RSA: Evaluation Hysterosonogram (HSN) Polyps Intrauterine Adhesions

  31. Uterine Factor & RSA: Treatment • Myomas, polyps, intrauterine adhesions usually removed hysteroscopically • Pre-op Lupron, lamineria, PGE1 analogue (e.g. misoprostol) • Outcomes comparable to abdominal procedures (Basko, 1997) • Septum repair: improved delivery rates; lower abortion rates (uncontrolled series, Hickok, 2000)

  32. Uterine Factor & RSA: Treatment • ACOG: “mixed results” for septum repair; association of RSA with polyps and myomas controversial • IVF with gestational surrogacy

  33. Infectious Agents & RSA • Listeria, ureaplasma, toxoplasmosis, viruses (e.g. rubella, HSV, CMV, Coxsackievirus, measles) have been associated with RSA in past • ACOG: “none are convincingly associated with RSA”

  34. Thrombophilia & RSA: Evaluation • ACOG Practice Bulletin: Testing for heritable thrombophilias in RSA not recommended; lack of evidence of association of thrombophilia with RSA, and lack of RCTs showing efficacy of antithrombotic therapy (ACOG Practice Bulletin, 2001) • Association between congenital or acquired thrombophilia and RSA vs. controls; strongest for 2nd, 3rd trimesters (Prestron et al., 1996)

  35. Thrombophilia & RSA: Evaluation • Maternal intervillous blood flow begins after 8 weeks • Studies support and refute: factor V Leiden mutation, prothrombin G20210A mutation, MTHFR C677T mutation, Protein C or S, and Antithrombin III deficiency (Regan et al., 1990)

  36. Thrombophilia & RSA: Treatment • Small, nonrandomized trials: low-dose heparin and aspirin increase the live birth rate in thrombophilic women with either early or late pregnancy loss (Brenner et al., 2000; Grandone et al., 2002) • Routine thromboprophylaxis during pregnancy cannot be recommended for women with thrombophilic abnormalities • If used, get hematologic consultation

  37. Antiphospholipid Antibody Syndrome & RSA: Evaluation • Lupus anticoagulant (LA) and/or anticardiolipin antibody (aCL) present in 15% of RSA vs. 2% controls (Stenchever et al., 2001; Li, 1998) • ACOG: One or both present on 2 occasions, > 6 weeks apart • IgG isotype of aCL most relevant; repeated IgM positive can be used to make diagnosis • If LA negative, aCL < 20 units of uncertain significance

  38. Antiphospholipid Antibody Syndrome & RSA: Treatment • Low dose heparin (5000 IU SQ BID) as effective as higher dose (Kutteh and Ermel, 1996) and better than asa alone (Kutteh, 1996) • RCT: prednisone and asa- no effect on subsequent delivery rates, more prematurity, premature rupture of membranes (Laskin et al., 1997) • ACOG: term rates 70-75% Hep/asa

  39. Antiphospholipid Antibody Syndrome & RSA: Treatment • Observational study (Rai et al., 2000) : No difference in term baby rates in early losses (805 women; asa 68%, no tx 65%) • Improved with late losses (250 women; asa 65%, no tx 49%) • IV IgG treatment for RSA not effective (Stephenson et al., 1998)

  40. Alloimmune Disorders & RSA • Hypothesis: Maternal immune response abnormality to semiallogeneic fetal “graft” linked to RSA • No good data to support this (23) (e.g. HLA typing) (Speroff et al., 1999) • Paternal leukocyte (mononuclear cell) transfusion not effective; may increase SAB risk (Ober et al., 1999) —ACOG concurs

  41. Endocrine Disorders & RSA • Hypothyroidism, no  risk; but, antithyroid antibodies marker for SAB risk (Stenchever et al., 2001) • DM under control: no  risk of SAB (25) •  fasting insulin (>20 UmL) in women with RSA (Craig et al., 2002) • 2X  risk in anovulatory PCOS women (Stenchever et al., 2001; Barnes, 1997) • Controversial: Metformin  SAB risk (Glueck et al., 2001; Jakubowicz et al., 2002; Heard et al., 2002)

  42. Endocrine Disorders & RSA: Luteal Phase Defect • No difference in P4 levels in RSA pts going to term with next pregnancy versus having another abortion (Ogasawara et al., 1997) • No difference in out of phase specimens for patients with infertility, normal fertility and RSA (Peters et al., 1992) • ACOG: association between LPD and RSA is “speculative”

  43. Unexplained RSA • 3 prospective, non-randomized trials found “tender loving care” significantly decreased the risk of subsequent abortion in women with RSA (Stenchever et al., 2001; Clifford et al., 1997) • Weekly U/S 5-12 weeks; reassurance if viability and normal growth seen; easy nurse and physician access

  44. Incompetent Cervix • Painless cervical dilation in second trimester, and spontaneously ruptured membranes • Etiology: previous cervical trauma (D&C, conization, cauterization), abnormal cervical development (e.g. in utero DES exposure)

  45. Incompetent Cervix: Pre-op Evaluation • Surgical treatment to reinforce weak cervix with purse string suture • U/S to exclude major fetal anomalies • Cultures for GC, CT, group B Strep • Delay until after 14 weeks • No consensus on how late (24-26 weeks?)

  46. Incompetent Cervix: Treatment • McDonald cerclage (1963) • Shirodkar operation (1955) • Modified Shirodkar cerclage (Caspi et al., 1990) • Less trauma & blood loss vs. Shirodkar • 85-90% success rate • Reserved for previous McDonald failures

  47. Pregnancy Loss Gregory Zapantis, M.D. Assistant Professor Albert Einstein College of Medicine Montefiore Institute for Reproductive Medicine & Health Hartsdale, NY (914) 997-1060

More Related